Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Catechol O-methyltransferase domain-containing protein 1 (COMTD1) is a human mitochondrial membrane-associated enzyme predicted to possess S-adenosylmethionine-dependent methyltransferase activity[1][2][3]. It shares sequence and structural similarity with the catechol-O-methyltransferase family. COMTD1 is ubiquitously expressed, with highest levels in tissues such as the gall bladder, small intestine, parathyroid gland, and kidney[2]. Its biological function is not fully established in humans, but in animal models, it is associated with regulation of mitochondrial metabolism, modulation of the oxidative stress response in pigment cells, and the synthesis of pheomelanin (a form of melanin pigment)[2]. Inactivation of COMTD1 in animal models alters various mitochondrial metabolic pathways and reduces pheomelanin synthesis but does not show evidence of involvement in well-characterized human diseases or therapeutic targeting to date[2].
Not established for any drugs; putative methyltransferase activity
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Catechol O-methyltransferase domain-containing protein 1 (COMTD1).